Senescent cells are cells that have permanently halted their cell cycle ('replicative arrest') but resist apoptosissometimes called 'zombie cells.' They accumulate with age in multiple tissues and secrete a pro-inflammatory cocktail called the Senescence-Associated Secretory Phenotype (SASP), containing IL-6, IL-8, MMP-3, MMP-9, TNF-, and other factors that damage surrounding healthy tissue
Proudly made in USA using the most advanced patented Liposomal technology
In late-stage trials, the combination of cagrilintide and semaglutide (CagriSema) produced significantly more weight loss than semaglutide alone
The most frequently reported reactions include: Redness (erythema) at the application site Itching or a tingling/stinging sensation , especially on freshly exfoliated or compromised skin Dryness or mild flaking , sometimes related to the overall formulation rather than the peptide itself Temporary irritation when combined with strong actives These reactions typically resolve on their own or after reducing frequency of use

Twice-daily dosing: Best for acute injuries Maintains more consistent peptide levels Often used for the first 12 weeks Morning and evening Total daily dose can be split between injections Once-daily dosing: Suitable for chronic conditions More convenient for long-term protocols Often used after the early healing phase Morning dosing is often preferred Full daily dose in a single injection Timing factors: Can be administered any time of day Consistent timing improves adherence No specific relationship to meals needed No specific timing relative to exercise needed Many researchers prefer morning dosing for convenience Localized vs
Five more peptides are slated for review next February